TG4001 2024
Category: dates
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
SITC 2024
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
H1 2024 FINANCIAL RESULTS
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
BT-001 ESMO
Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
S. Champiat, et al. ESMO 2024 Abstract available on the ESMO website – Download the abstract and the poster
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment
L.Fend, et al. ESMO 2024 Abstract available on the CICON website – Download the abstract and the poster
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Nominations
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
ESMO ABSTRACT
Transgene to Participate in HTID Conference and Investor Access Forum in Paris
investor events
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
Article available on The Journal for ImmunoTherapy of Cancer (JITC)